Skip to main content
OpenTrials

Clinical trial condition

Sudden Infant Death

Explore clinical trials studying Sudden Infant Death. Study availability and eligibility vary by location and protocol.

61 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

Sudden Infant Death trial results

Enrolling by invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

NCT06075537

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +22 more
Locations
  • UCSF Benioff Children's Hospital Oakland Oakland, California, United States
  • Ann and Robert H Lurie Children's Hospital of Chicago Chicago, Illinois, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • UNC Children's Research Institute Chapel Hill, North Carolina, United States
View all 29 locations
View Trial Details
Active, not recruiting

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

NCT05208281

Conditions
Carbohydrate Metabolism, Inborn Errors, Cognition Disorders, Cognitive Dysfunction, +30 more
Locations
  • Federal State-Funded Healthcare Institution Central Clinical Hospital of the Russian Academy of Sciences (Research Institute of Pediatrics and Child Health Protection of the Central Clinical Hospital of the Russian Academy of Sciences) Moscow, Russia
  • Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation Saint Petersburg, Russia
  • V.I. Vernadsky Crimean Federal University Simferopol, Russia
  • State Budgetary Healthcare Institution Republican Medical Genetic Center Ufa, Russia
View Trial Details
Active, not recruiting

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

NCT05371613

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +22 more
Locations
  • UCSF Benioff Children's Hospital Oakland Oakland, California, United States
  • Ann and Robert H Lurie Children's Hospital of Chicago Chicago, Illinois, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • UNC Children's Research Institute Chapel Hill, North Carolina, United States
View all 30 locations
View Trial Details
Active, not recruiting

Long-term Follow-Up for RGX-121

NCT04597385

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +22 more
Locations
  • University of California, San Francisco (UCSF)- Benioff Children's Hospital San Francisco, California, United States
  • Saint Peter's Healthcare System New Brunswich, New Jersey, United States
  • The Children's Hospital of Philadelphia (CHOP) Philadelphia, Pennsylvania, United States
  • Hospital de Clinicas de Porto Alegre Porto Alegre, Brazil
View Trial Details
Active, not recruiting

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

NCT04251026

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +22 more
Locations
  • UCSF Benioff Children's Hospital Oakland, California, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States
  • UNC Children's Research Institute Chapel Hill, North Carolina, United States
  • UPMC | Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania, United States
View Trial Details
Active, not recruiting

CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)

NCT03566043

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +23 more
Locations
  • University of California San Francisco, Benioff Children's Hospital Oakland, California, United States
  • St. Peter's University Hospital New Brunswick, New Jersey, United States
  • Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States
  • Children's Hospital of Pittsburgh - UPMC: Program for Neurodevelopment in Rare Disorders Pittsburgh, Pennsylvania, United States
View Trial Details

Related conditions